Aelis Farma Future Growth

Future criteria checks 4/6

Aelis Farma is forecast to grow earnings and revenue by 17.2% and 15.2% per annum respectively. EPS is expected to decline by 21.8% per annum. Return on equity is forecast to be -36% in 3 years.

Key information

17.2%

Earnings growth rate

-21.8%

EPS growth rate

Biotechs earnings growth	8.5%
Revenue growth rate	15.2%
Future return on equity	-36.0%
Analyst coverage	Low
Last updated	14 Oct 2024

Recent future growth updates

Recent updates

Aelis Farma SA's (EPA:AELIS) 49% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Sep 06

Some Confidence Is Lacking In Aelis Farma SA (EPA:AELIS) As Shares Slide 49%

Sep 06

Earnings and Revenue Growth Forecasts

ENXTPA:AELIS - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	3	-13	-16	-8	2
12/31/2025	58	40	-21	42	2
12/31/2024	5	-10	-18	-11	2
6/30/2024	11	-7	-13	-13	N/A
3/31/2024	12	-6	-13	-13	N/A
12/31/2023	12	-5	-13	-13	N/A
9/30/2023	11	-5	-13	-13	N/A
6/30/2023	10	-6	-13	-13	N/A
3/31/2023	9	-10	-13	-13	N/A
12/31/2022	8	-14	-13	-13	N/A
9/30/2022	8	-14	-14	-13	N/A
6/30/2022	7	-14	-14	-14	N/A
3/31/2022	9	-6	2	3	N/A
12/31/2021	11	1	19	19	N/A
9/30/2021	10	2	21	21	N/A
6/30/2021	9	3	24	24	N/A
3/31/2021	5	1	11	11	N/A
12/31/2020	1	-2	-3	-2	N/A
12/31/2019	0	-3	N/A	N/A	N/A
12/31/2018	0	-3	N/A	N/A	N/A
12/31/2017	0	-1	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AELIS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).

Earnings vs Market: AELIS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AELIS is expected to become profitable in the next 3 years.

Revenue vs Market: AELIS's revenue (15.2% per year) is forecast to grow faster than the French market (5.6% per year).

High Growth Revenue: AELIS's revenue (15.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AELIS is forecast to be unprofitable in 3 years.

Aelis Farma Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Price target decreased by 27% to €15.00

Consensus EPS estimates upgraded to €1.36 loss

Recent updates

First half 2024 earnings released: €0.27 loss per share (vs €0.13 loss in 1H 2023)

Aelis Farma SA's (EPA:AELIS) 49% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Some Confidence Is Lacking In Aelis Farma SA (EPA:AELIS) As Shares Slide 49%

New major risk - Share price stability

Price target decreased by 27% to €15.00

Aelis Farma Announces the Results of Its Clinical Phase 2B Study with AEF0117, Among Participants with Cannabis Use Disorder (CUD)

Aelis Farma SA Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder

Full year 2023 earnings released

Aelis Farma SA, Annual General Meeting, Jun 04, 2024

Aelis Farma Announces the Appointment of Arsène Guekam as Chief Corporate Development Officer

Aelis Farma Announces Completion of Patient Randomization for Phase 2B Study with Aef0117 for the Treatment of Cannabis Addiction

Aelis Farma Announces Positive Results of Non-Clinical Studies Required by Regulatory Agencies to Enter Its First Cb1-SSI, AEF0117, in Phase 3 Clinical Trial for the Treatment of Cannabis Use Disorder

New minor risk - Shareholder dilution

First half 2023 earnings released

Aelis Farma Receives a Positive Recommendation From the DSMB to Continue, With No Modification to the Protocol, the Phase 2b Clinical Study With AEF0117 in Cannabis Addiction

Consensus EPS estimates upgraded to €1.36 loss

Aelis Farma Announces the Presentation of New Preclinical Data on its Drug Candidate AEF0217 at the 2nd European Conference on Phelan-McDermid Syndrome

Full year 2022 earnings released

Aelis Farma SA, Annual General Meeting, May 24, 2023

Aelis Farma S.A Announces the Recruitment of the First Patient for the Phase 1/2 Clinical Trial of Its Drug Candidate AEF0217 for the Treatment of Cognitive Disorders in Down Syndrome

High number of new directors

Aelis Farma Announces Positive Results from Its Safety Trials in Healthy Volunteers and the Authorization to Start the First Trial in People with Down Syndrome with AEF0217

First half 2022 earnings released

Aelis Farma S.A. Announces the Inclusion of the 1st Patient in A Phase 2B Study of AEF0117 for the Treatment of Cannabis Use Disorder

High number of new directors

Full year 2021 earnings released

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies